244 related articles for article (PubMed ID: 27612149)
1. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.
Emmert S; Haenssle HA; Zibert JR; Schön M; Hald A; Hansen MH; Litman T; Schön MP
PLoS One; 2016; 11(9):e0160096. PubMed ID: 27612149
[TBL] [Abstract][Full Text] [Related]
2. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
5. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
6. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.
Segura S; Gadea A; Nonell L; Andrades E; Sánchez S; Pujol R; Hernández-Muñoz I; Toll A
PLoS One; 2020; 15(5):e0232146. PubMed ID: 32413042
[TBL] [Abstract][Full Text] [Related]
7. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
8. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
[TBL] [Abstract][Full Text] [Related]
9. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
12. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
13. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
14. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response.
Rosen RH; Gupta AK; Tyring SK
J Am Acad Dermatol; 2012 Mar; 66(3):486-93. PubMed ID: 22055282
[TBL] [Abstract][Full Text] [Related]
15. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
16. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
17. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
20. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
